DE602005026313D1 - Pharmazeutische formulierungen von decitabin - Google Patents

Pharmazeutische formulierungen von decitabin

Info

Publication number
DE602005026313D1
DE602005026313D1 DE602005026313T DE602005026313T DE602005026313D1 DE 602005026313 D1 DE602005026313 D1 DE 602005026313D1 DE 602005026313 T DE602005026313 T DE 602005026313T DE 602005026313 T DE602005026313 T DE 602005026313T DE 602005026313 D1 DE602005026313 D1 DE 602005026313D1
Authority
DE
Germany
Prior art keywords
pharmaceutical formulations
decitabine
methods
decitabin
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005026313T
Other languages
English (en)
Inventor
Chunlin Tang
Rajashree Joshi-Hangal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Pharmaceuticals Inc
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc filed Critical Supergen Inc
Publication of DE602005026313D1 publication Critical patent/DE602005026313D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
DE602005026313T 2004-12-10 2005-12-08 Pharmazeutische formulierungen von decitabin Active DE602005026313D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/009,540 US20060128653A1 (en) 2004-12-10 2004-12-10 Pharmaceutical formulation of decitabine
PCT/US2005/044676 WO2006071491A1 (en) 2004-12-10 2005-12-08 Pharmaceutical formulation of decitabine

Publications (1)

Publication Number Publication Date
DE602005026313D1 true DE602005026313D1 (de) 2011-03-24

Family

ID=36584811

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005026313T Active DE602005026313D1 (de) 2004-12-10 2005-12-08 Pharmazeutische formulierungen von decitabin

Country Status (15)

Country Link
US (1) US20060128653A1 (de)
EP (1) EP1819227B1 (de)
JP (1) JP5227029B2 (de)
AT (1) ATE497770T1 (de)
AU (1) AU2005322369B2 (de)
CA (1) CA2589052A1 (de)
CY (1) CY1111433T1 (de)
DE (1) DE602005026313D1 (de)
DK (1) DK1819227T3 (de)
ES (1) ES2360125T3 (de)
HK (1) HK1102991A1 (de)
PL (1) PL1819227T3 (de)
PT (1) PT1819227E (de)
SI (1) SI1819227T1 (de)
WO (1) WO2006071491A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070105792A1 (en) * 2005-11-04 2007-05-10 Dimartino Jorge F Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
US20090075920A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched decitabine
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
ES2525257T3 (es) * 2009-02-25 2014-12-19 Supratek Pharma, Inc. Composiciones de ciclopolisacárido y de bendamustina
US8383663B2 (en) * 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
US10052345B2 (en) 2010-10-19 2018-08-21 University Of Miami Assays, methods and kits for predicting renal disease and personalized treatment strategies
EP2670396A1 (de) * 2011-01-31 2013-12-11 Celgene Corporation Pharmazeutische zusammensetzungen aus cytidinanaloga und anwendungsverfahren dafür
ES2547920T3 (es) * 2011-07-01 2015-10-09 Fondazione Istituto Insubrico Di Ricerca Per La Vita Un complejo de tomoxiprol amorfo y ciclodextrina con una rápida velocidad de disolución y procedimiento para su preparación
KR102004559B1 (ko) 2011-08-30 2019-07-26 아스텍스 파마수티컬스, 인크. 데시타빈 유도체 제제
JP6508944B2 (ja) 2012-02-15 2019-05-08 サイデックス・ファーマシューティカルズ・インコーポレイテッド シクロデキストリン誘導体のための製造方法
CA2865950C (en) 2012-02-28 2016-12-20 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP4299121A2 (de) 2012-04-13 2024-01-03 L&F Research LLC Verfahren zur verwendung von cyclodextrin
US9493500B2 (en) 2012-07-19 2016-11-15 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
MX360192B (es) 2012-10-22 2018-10-24 Cydex Pharmaceuticals Inc Composiciones de ciclodextrinas alquiladas y procesos para preparar y usar las mismas.
ES2877103T3 (es) * 2013-03-15 2021-11-16 Epigenetics Pharma Llc Análogos de pirimidina fluorados y métodos de uso de los mismos
CA2903300A1 (en) * 2013-03-15 2014-09-25 Epizyme, Inc. Injectable formulations for treating cancer
CA2939581C (en) * 2014-02-20 2024-01-23 Vaxart, Inc. Formulations for small intestinal delivery
US9474756B2 (en) * 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10851184B2 (en) 2014-08-22 2020-12-01 Cydex Pharmaceuticals, Inc. Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
CA2960287A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Injectable formulations for treating cancer
CN104887632B (zh) * 2015-05-25 2017-10-24 连云港杰瑞药业有限公司 一种地西他滨冻干制剂的制备方法及其产品
EP3307239B1 (de) 2015-06-12 2020-09-16 Vaxart, Inc. Formulierungen zur freisetzung von rsv- und norovirus-antigenen im dünndarm
JP6768722B2 (ja) * 2015-07-02 2020-10-14 大塚製薬株式会社 凍結乾燥医薬組成物
MX2018006790A (es) 2015-12-03 2019-05-02 Epidestiny Inc Composiciones que contienen decitabina, 5azacitidina y etrahidrouridina y sus usos.
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo
WO2023203249A1 (en) * 2022-04-22 2023-10-26 Universität Heidelberg Composition comprising cytidine analogs and uses and methods thereof
WO2024028790A1 (en) * 2022-08-03 2024-02-08 Beren Therapeutics P.B.C. Compositions and methods for treating sickle cell disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
US4684630A (en) * 1983-08-24 1987-08-04 Repta Arnold J Method of parenterally delivering drugs and related compositions
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5856090A (en) * 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
US5856094A (en) * 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
EP0876149A4 (de) * 1995-12-22 2001-09-26 Univ East Carolina Verfahren zur behandlung von störungen, die von einer cytidin- deaminase oder desoxycytidin- deaminase überexpression charakteriziert werden
US6423692B2 (en) * 1997-04-24 2002-07-23 Dana-Farber Cancer Institute, Inc. Method of enhancing the effectiveness of DCK phosphorylated molecules
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
AU5128999A (en) * 1998-07-24 2000-02-14 Yeda Research And Development Co. Ltd. Prevention of metastasis with 5-aza-2'-deoxycytidine
US20020136709A1 (en) * 2000-12-12 2002-09-26 Nucleus Remodeling, Inc. In vitro-derived adult pluripotent stem cells and uses therefor
US20030165864A1 (en) * 2001-01-16 2003-09-04 Lasek Amy W. Genes regulated by DNA methylation in tumor cells
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
US20030013099A1 (en) * 2001-03-19 2003-01-16 Lasek Amy K. W. Genes regulated by DNA methylation in colon tumors
CA2444894C (en) * 2001-04-26 2013-06-25 Control Delivery Systems, Inc. Sustained release drug delivery system containing codrugs
US20030045497A1 (en) * 2001-07-27 2003-03-06 Geneinvent Bbl Ab Methylation resistant vectors
IN2014DN10834A (de) * 2001-09-17 2015-09-04 Psivida Inc
US20030147813A1 (en) * 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia
US6927036B2 (en) * 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
WO2005014010A1 (en) * 2003-07-24 2005-02-17 Eli Lilly And Company Pharmaceutical composition comprising gemcitabine and cyclodextrines
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine

Also Published As

Publication number Publication date
PL1819227T3 (pl) 2011-07-29
JP5227029B2 (ja) 2013-07-03
WO2006071491A1 (en) 2006-07-06
JP2008523096A (ja) 2008-07-03
EP1819227B1 (de) 2011-02-09
ES2360125T3 (es) 2011-06-01
SI1819227T1 (sl) 2011-06-30
CY1111433T1 (el) 2015-08-05
PT1819227E (pt) 2011-04-29
AU2005322369B2 (en) 2010-10-28
EP1819227A1 (de) 2007-08-22
HK1102991A1 (en) 2007-12-14
US20060128653A1 (en) 2006-06-15
ATE497770T1 (de) 2011-02-15
AU2005322369A1 (en) 2006-07-06
CA2589052A1 (en) 2006-07-06
EP1819227A4 (de) 2008-07-23
DK1819227T3 (da) 2011-05-30

Similar Documents

Publication Publication Date Title
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
WO2006063111A3 (en) Pharmaceutical formulations cytidine analogs and derivatives
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
WO2006029081A3 (en) Nucleoside-lipid conjugates, their method of preparation and uses thereof
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
SE0001899D0 (sv) New compounds
CY1118179T1 (el) Φαρμακευτικη συνθεση
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
EA200802213A1 (ru) Способы лечения заболеваний крови
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
ATE494899T1 (de) Zusammensetzung bestehend aus phy906 und chemotherapeutika
WO2006053049A3 (en) Herbal composition phy906 and its use in chemotherapy
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
EA200401114A2 (ru) Замещённые гидроксиэтиламины
SE0401342D0 (sv) Therapeutic compounds
BRPI0513287A (pt) derivados de pirido-pirimidina, sua preparação, sua aplicação em terapêutica
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
NO20071798L (no) Dermalt pafore formuleringer for behandling av hudsykdommer i dyr
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
WO2006108679A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer